Outcomes of first-line pembrolizumab monotherapy for PD-L1-positive (TPS ≥50%) metastatic NSCLC at US oncology practices

Immunotherapy, Ahead of Print.

Source: Immunotherapy - November 27, 2019 Category: Allergy & Immunology Authors: Vamsidhar Velcheti Sheenu Chandwani Xin Chen M Catherine Pietanza Bilal Piperdi Thomas Burke Source Type: research